Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome.
Pneumocystis carinii pneumonia (PCP) is an important cause of acute respiratory failure in HIV-infected children. PCP may initiate acute respiratory distress syndrome (ARDS) by adversely affecting surfactant physiology. We report improved pulmonary function following administration of bovine lipid extract surfactant to two infants with AIDS-related PCP/ARDS.
Creery
W D
WD
Department of Pediatrics, University of Ottawa, Ontario, Canada.
Hashmi
A
A
Hutchison
J S
JS
Singh
R N
RN
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000818:Animals; D001784:Blood Gas Analysis; D002417:Cattle; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000378:metabolism / Q000469:parasitology
D011663:Pulmonary Surfactants